Matthew Wisnieff

Matthew Wisnieff is a senior litigation associate in the New York office and a member of the Firm's Intellectual Property global practice. Matthew represents domestic and foreign clients in complex commercial litigation, focusing on intellectual property disputes as well as matters concerning the intersection of patent and antitrust law. He regularly represents industry leaders in the pharmaceutical, medical device, and technology industries, such as Allergan/AbbVie, Pfizer, Boehringer Ingelheim, and Abiomed, at both the trial and appellate levels.

Matthew's practice covers a wide range of matters, including patent, trademark, trade secret, and copyright disputes, litigation under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act, class action litigation, IP licensing disputes, and advising clients on patent and antitrust law. In addition to high-stakes IP matters, Matthew has extensive experience litigating the IP aspects of pharmaceutical-antitrust cases and standard-essential patent (SEP)/FRAND disputes. Recently, Matthew successfully represented CosmoKey in a significant decision before the Court of Appeals for the Federal Circuit, winning a rare reversal under the Alice doctrine. In the past, he has also participated in litigation through trial of federal bankruptcy proceedings arising out of the 2008 financial crisis.

Matthew also has extensive experience representing pro bono clients in the area of environmental law. He regularly litigates and advises on Clean Water Act enforcement disputes on behalf of an environmental nonprofit organization. In the past, Matthew has provided legal advice assisting parents of New York City public school students in prevailing in an environmental dispute under the Resource Conservation and Recovery Act.